ARTICLE | Clinical News

Nuplazid: Ph II CLARITY started

December 6, 2016 8:04 PM UTC

Acadia began the double-blind, placebo-controlled Phase II CLARITY trial to evaluate 34 mg oral Nuplazid once daily for 10 weeks plus ongoing antidepressant therapy in about 188 patients. CLARITY will...

BCIQ Company Profiles

Acadia Pharmaceuticals Inc.

BCIQ Target Profiles

Serotonin (5-HT2A) receptor